Minretumomab

Minretumomab
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	TAG-72
Clinical data
ATC code	V09IX03 (WHO) (¹²⁵I radiolabelled)
Identifiers
Synonyms	CC49
CAS Number	195189-17-4^N
ChemSpider	none
^NY (what is this?) (verify)

Minretumomab (CC49) is a mouse monoclonal antibody^[1] that was designed for the treatment of cancers that express the TAG-72 antigen. This includes breast, colon, lung, and pancreatic cancers.^[2]^[3] Apparently, it never got past Phase I clinical trials for this purpose.^[4]

Derivatives

A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric^[5] and humanized minretumomab,^[6] as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase.^[7]

Radiopharmaceuticals

Iodine (¹²⁵I) minretumomab is an iodine-125 radiolabelled derivative that was developed for the detection of tumours in radioimmunoassays such as CA 72-4.^[8]

Radiolabelled minretumomab has also been tested for the treatment of solid tumours, but without success. Iodine (¹³¹I) and lutetium (¹⁷⁷Lu) minretumomab, for example, were shown to induce human anti-mouse antibodies; no tumour response was observed in Phase I and II clinical trials.^[5]

References

↑ WHO Drug Information.
↑ TAG-72 antigen entry in the public domain NCI Dictionary of Cancer Terms.
↑ Scott, Andrew M.; Wolchok, Jedd D.; Old, Lloyd J. (2012). "Antibody therapy of cancer". Nature Reviews Cancer. 12 (4): 278. PMID 22437872. doi:10.1038/nrc3236.
↑ CC49 on ClinicalTrials.gov.
1 2 Trahan Rieger, Paula, ed. (2001). Biotherapy (2nd ed.). Jones and Bartlett. pp. 334–335. ISBN 0-7637-1428-3.
↑ Milenic, D. E.; Brady, E. D.; Garmestani, K.; Albert, P. S.; Abdulla, A.; Brechbiel, M. W. (2010). "Improved efficacy of α-particle-targeted radiation therapy". Cancer. 116 (4 Suppl): 1059–1066. PMID 20127951. doi:10.1002/cncr.24793.
↑ Alderson, R. F.; Toki, B. E.; Roberge, M.; Geng, W.; Basler, J.; Chin, R.; Liu, A.; Ueda, R.; Hodges, D.; Escandon, E.; Chen, T.; Kanavarioti, T.; Babé, L.; Senter, P. D.; Fox, J. A.; Schellenberger, V. (2006). "Characterization of a CC49-Based Single-Chain Fragment−β-Lactamase Fusion Protein for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)". Bioconjugate Chemistry. 17 (2): 410–418. PMID 16536473. doi:10.1021/bc0503521.
↑ Guadagni, F.; Roselli, M.; Cosimelli, M.; Spila, A.; Cavaliere, F.; Tedesco, M.; Arcuri, R.; Abbolito, M. R.; Casale, V.; Pericoli, M. N.; Vecchione, A.; Casciani, C. U.; Greiner, J. W.; Schlom, J. (1996). "Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay". Cancer Research. 56 (22): 5293–5298. PMID 8912871.

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")

Human ("-tumu-")	Adecatumumab^§ Ascrinvacumab^§ Cixutumumab^§ Conatumumab^§ Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin^§ Enoticumab^§ Figitumumab^§ Ganitumab^† Glembatumumab vedotin^§ Intetumumab^§ Ipilimumab Iratumumab^§ Icrucumab^§ Lexatumumab^§ Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Tarextumab^§ Teprotumumab^§ Tovetumab^§ Vantictumab^§ Vesencumab^§ Votumumab^§ Zalutumumab^† "-melu-" (melanoma) Flanvotumab^§
Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Detumomab Ibritumomab tiuxetan Minretumomab Mitumomab Moxetumomab pasudotox Naptumomab estafenatox Nofetumomab merpentan Pemtumomab^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor) Abagovomab Igovomab Oregovomab "-pro-" (prostate tumor) Capromab pendetide "-colo-" (colonic tumor) Edrecolomab Nacolomab tafenatox
Chimeric ("-tuxi-")	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Cetuximab Derlotuximab biotin^§ Dinutuximab Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab^† Margetuximab^† Rituximab^# Siltuximab Ublituximab^§ "-mexi-" (melanoma): Ecromeximab^§
Humanized ("-tuzu-")	Abituzumab^§ Alemtuzumab Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Citatuzumab bogatox^§ Clivatuzumab tetraxetan Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Denintuzumab mafodotin^§ Elotuzumab Emactuzumab^§ Emibetuzumab^§ Enoblituzumab^§ Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Gemtuzumab ozogamicin^‡ Imgatuzumab^§ Inotuzumab ozogamicin^† Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^§ Parsatuzumab^§ Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin^§ Sibrotuzumab^§ Simtuzumab^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ "-gozu-" (ovarian tumor) Sofituzumab vedotin^§
Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab^§
Chimeric + humanized ("-tuxizu-")	Depatuxizumab mafodotin^§ Ontuxizumab^§
Veterinary ("-tuvet-")	Blontuvetmab^§ Tamtuvetmab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.